| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Fennec Pharmaceuticals (NASDAQ:FENC) is set to give its latest quarterly earnings report on Monday, 2023-11-06. Here's what investors need to know before the announcement.
Analysts estimate that Fennec Pharmaceuticals will report an earnings per share (EPS) of $-0.11.
Fennec Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Last quarter the company missed EPS by $0.05, which was followed by a 0.25% increase in the share price the next day.
Here's a look at Fennec Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.16 | -0.21 | -0.26 | |
| EPS Actual | -0.21 | -0.23 | -0.26 | -0.31 |
| Price Change % | 0.25% | -4.57% | -2.69% | 0.49% |
Shares of Fennec Pharmaceuticals were trading at $6.96 as of November 02. Over the last 52-week period, shares are down 18.54%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all earnings releases for Fennec Pharmaceuticals visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: FENC
